EP0809653B1 - Helicobacter pylori antigen - Google Patents

Helicobacter pylori antigen Download PDF

Info

Publication number
EP0809653B1
EP0809653B1 EP96902390A EP96902390A EP0809653B1 EP 0809653 B1 EP0809653 B1 EP 0809653B1 EP 96902390 A EP96902390 A EP 96902390A EP 96902390 A EP96902390 A EP 96902390A EP 0809653 B1 EP0809653 B1 EP 0809653B1
Authority
EP
European Patent Office
Prior art keywords
protein
pylori
composition
antigenic fragment
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP96902390A
Other languages
English (en)
French (fr)
Other versions
EP0809653A1 (de
Inventor
Christopher John Smith
Robert Llewellyn University Of Newcastle Clancy
Allan Cripps
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cortecs Ltd
Original Assignee
Provalis UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provalis UK Ltd filed Critical Provalis UK Ltd
Publication of EP0809653A1 publication Critical patent/EP0809653A1/de
Application granted granted Critical
Publication of EP0809653B1 publication Critical patent/EP0809653B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/106—Vibrio; Campylobacter; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • the present invention relates to a novel antigen of Helicobacter pylori, or antigenic fragments thereof, the use of the antigen or fragments thereof in detecting Helictobacter pylori and kits comprising them, as well as vaccines comprising the antigen or fragments thereof and a method for isolation of the antigen.
  • This response often initially parallels an antibody response in serum although is generally characterised by the presence of IgA antibodies.
  • the immune response in secretion, including saliva rapidly diminishes following elimination of the antigen (eg bacteria or virus) from the body. Accordingly, the presence of antibody in mucous secretions reflects current, ie contemporary, infection.
  • secretious antibodies reflect the current status of colonisation of the microbe, such as in the gut, and thus is a useful monitor of contemporary infection.
  • Serum antibody persists for some time after the microbe is eliminated from the body.
  • a positive serum antibody test therefore, reflects both past and present exposure to antigen which is less helpful to the clinician.
  • a positive secretious antibody test indicates present or contemporary infection by the microbe.
  • H. pylori infection can be made by microscopy, microbiological culture or urease detection in gastric mucosal biopsies, urea breath test or by the presence of specific antibodies in serum ELISAs. It might be predicted that H. pylori infection, being an infection of the gastric mucosa, would elicit an IgA antibody response in gastric secretion. However, it has been discovered that H. pylori -specific antibody in mucous secretions is of the IgG class and not IgA as might have been expected. Little IgA antibody, if any, is detected. Accordingly, AU-A-9067676 is directed to the detection of IgG in mucous secretion specific to H. pylori antigen and thereby provides a means of monitoring current, ie contemporary, infection by that microorganism in mammals. The corresponding academic publication is Witt et al , Frontiers in Mucosal Immunology 1 693-696 (1991).
  • WO-A-9322682 discloses a convenient and reliable in vitro test for H. pylori. This test utilises an antigen preparation in a reaction with IgG antibody in a mucous secretion from a mammal being tested.
  • H. pylori novel antigens from H . pylori which can be used in diagnostic tests. These antigens should be specific, reliably purifiable, and should be characterised by good specificity and the lack of false positive results when used in such tests. In addition they may also form the basis of a vaccine useful either for the treatment or prophylaxis of H.pylori infection.
  • H. pylori Various proteins derived from H. pylori have been isolated and characterised and examples of such proteins include those disclosed in Evans et al, Infection and Immunity, 60(5), 2125-2127, (1992), EP-A-0329570 and Kostrzynska et al, J. Bacteriol., 173(3)., 937-946 (1991).
  • the present inventin relates to a novel antigenic protein derived from H. pyroli which can be used in diagnostic tests or from the basis of a vaccine.
  • the present invention provides a protein being an H. pylori antigen and having a molecular weight in the range 55-65 kDa, as determined under denaturing and reducing conditions.
  • the antigenic protein has, at its amino terminal end, the following amino acid sequence: or a sequence substantially homologous thereto.
  • a protein sequence may be regarded as substantially homologous to another protein sequence if a significant number of the constituent amino acids exhibit homology. At least 40%, 50%, 60%, 70%, 80%, 90%, 95% or even 99%, in increasing order of preference, of the amino acids may be homologous.
  • the present invention provides an antigenic fragment of the protein of the invention.
  • the antigenic fragment is a peptide having the sequence:
  • the antigenic protein, or fragments thereof, of the present invention can be provided alone, as a purified or isolated preparation, or as part of a mixture with other H. pylori antigenic proteins.
  • the invention provides an antigen composition comprising a protein of the invention and or one or more antigenic fragments thereof.
  • a composition can be used for the detection and/or diagnosis of H. pylori.
  • the composition comprises one or more additional H. pylori antigens.
  • the present invention provides a method of detecting and/or diagnosing H. pylori which comprises:
  • the protein, antigenic fragment thereof or antigen composition of the invention can be used to detect IgG antibodies.
  • the sample to be tested will be a biological sample, e.g. a sample of blood or saliva.
  • An example of a suitable method for detection of H.pylori using a sample of a mucous secretion is that described in WO-A-9322682.
  • the invention provides the use of an antigenic protein, antigenic fragment thereof or antigenic composition of the present invention in detecting and /or diagnosing H. pylori.
  • the detecting and/or diagnosing is carried out in vitro.
  • the present invention provides a method of isolating an antigenic protein of the invention, which process comprises the following steps:
  • the antigenic protein, antigenic fragment thereof or antigen composition of the invention can be provided as part of a kit for use in in vitro detection and/or diagnosis of H. pylori.
  • the present invention provides a kit for use in the detection and/or diagnosis of H. pylori comprising an antigenic protein, antigenic fragment thereof or antigen composition of the invention.
  • the antigenic protein or antigenic fragment thereof of the invention can be used to induce an immune response against H. pylori.
  • the present invention provides a composition capable of eliciting an immune response in a subject which comprises the protein or one or more antigenic fragments thereof of the invention.
  • the composition will be a vaccine composition, optionally comprising one or other suitable adjuvants.
  • a vaccine composition may be either a prophylactic or therapeutic vaccine composition.
  • the vaccine compositions of the invention can include one or more adjuvants.
  • adjuvants well known in the art include inorganic gels such as aluminium hydroxide or water-in-oil emulsions such as incomplete Freund's adjuvant.
  • Other useful adjuvants will be well known to the skilled man.
  • the present invention provides:
  • Rabbits were inoculated with the peptide MVTLINNE. Blood samples were assayed as described below to test for antibody response.
  • the assays were carried out using plates wherein each well is coated with 100 ⁇ l of 5 ⁇ g/ml H. pylori antigen (antigen preparation as described in WO-A-93/22682), followed by 300 ⁇ l of 1% Byco A solution as a post coat.
  • CDL wash buffer quantities for 1 dm 3 Tris 12.11 g 5M HCl 15 ml Distilled water 400 ml NaCl 87.66 g Thiomersal 0.1 g Tween 80 50 g
  • Peroxidase citrate buffer quantities for 1 dm 3 Distilled water 700 ml Citric acid 23.0 g NaOH 100 ml 30% H 2 O 2 0.5 ml Adjust pH to 4.0 with 1M NaOH.
  • the assay protocol was as follows:
  • the peptide elicits an anti- H . pylori antibody response.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (15)

  1. Protein, bei dem es sich um ein H. pylori-Antigen handelt und welches ein Molekulargewicht im Bereich von 55-65 kDa aufweist, wie unter Denaturier- und Reduzierbedingungen bestimmt wurde, und welches an seinem Aminoende die Sequenz:
    Figure 00170001
       oder eine dazu im wesentlichen homologe Sequenz aufweist.
  2. Antigenes Fragment eines Proteins nach Anspruch 1.
  3. Antigenes Fragment nach Anspruch 2, welches die Sequenz:
    Figure 00170002
       oder eine dazu im wesentlichen homologe Sequenz aufweist.
  4. Antigenzusammensetzung, umfassend ein in Anspruch 1 definiertes Protein oder zumindest ein antigenes in Anspruch 2 oder Anspruch 3 definiertes Fragment.
  5. Antigenzusammensetzung nach Anspruch 4, welche weiters ein oder mehrere andere H. pylori-Antigene umfaßt.
  6. Protein nach Anspruch 1, antigenes Fragment nach Anspruch 2 oder Anspruch 3 oder Antigenzusammensetzung nach Anspruch 4 oder Anspruch 5 zur Verwendung bei der Feststellung und/oder Diagnose von H. pylori.
  7. Verfahren zum Feststellen und/oder Diagnostizieren von H. pylori, welches umfaßt:
    (a) Inkontaktbringen eines in Anspruch 1 definierten Proteins, zumindest eines antigenen in Anspruch 2 oder Anspruch 3 definierten Fragments oder einer in Anspruch 4 oder Anspruch 5 definierten Antigenzusammensetzung, mit einer zu prüfenden Probe; und
    (b) Feststellen des Vorliegens von Antikörpern auf H. pylori.
  8. Verfahren nach Anspruch 7, wobei es sich bei der Probe um eine Speichelprobe handelt.
  9. Verwendung eines in Anspruch 1 definierten Proteins, zumindest eines antigenen in Anspruch 2 oder Anspruch 3 definierten Fragments oder einer in Anspruch 4 oder Anspruch 5 definierten Antigenzusammensetzung beim Feststellen und/oder Diagnostizieren von H. pylori.
  10. Verfahren nach Anspruch 7 oder Anspruch 8 oder Verwendung nach Anspruch 9, wobei das Feststellen und/oder Diagnostizieren in vitro erfolgt.
  11. Verfahren zum Isolieren eines Proteins nach Anspruch 1, welches umfaßt:
    (a) Anlegen von Kulturen von H. pylori, Züchten der Kulturen in geeigneten Bedingungen und Emten derselben, gefolgt von Waschen, um ein gewaschenes Zellpellet zu erhalten;
    (b) Resuspendieren der gewaschenen Zellen in einem geeigneten Puffer, gefolgt vom Zerschlagen der Zellen;
    (c) Zentrifugieren, um Zelltrümmer zu entfernen, Gewinnen des Überstandes, welcher lösliche Zellproteine enthält;
    (d) Unterziehen der erhaltenen Lösung einer Ionenaustauschchromatographie mit einer Gradientenelution und Analysieren der auf diese Weise erhaltenen Fraktionen auf die Gegenwart von Urease;
    (e) Vereinigen der ureasehaltigen Fraktionen und Unterziehen der vereinigten Fraktionen einer Gel-Permeationschromatographie;
    (f) Auswählen der geeigneten Spitze; und
    (g) Bestätigen der Gegenwart des spezifischen Proteins, welches ein Molekulargewicht im Bereich von 55-65 kDa im Isolat aufweist, und Isolieren des Proteins.
  12. Set zur Verwendung bei der Feststellung und/oder Diagnose von H. pylori, umfassend ein in Anspruch Idefiniertes Protein, zumindest ein antigenes in Anspruch 2 oder Anspruch 3 definiertes Fragment oder eine in Anspruch 4 oder Anspruch 5 definierte Antigenzusammensetzung.
  13. Zusammensetzung, welche in der Lage ist, eine Immunantwort in einem Subjekt hervorzurufen, und welche ein in Anspruch 1 definiertes Protein, zumindest ein antigenes in Anspruch 2 oder Anspruch 3 definiertes Fragment oder eine in Anspruch 4 oder Anspruch 5 definierte Antigenzusammensetzung umfaßt.
  14. Zusammensetzung nach Anspruch 13, welche eine Impfstoffzusammensetzung ist, die wahlweise weiters einen oder mehrere Hilfsstoffe umfaßt.
  15. Verwendung eines in Anspruch 1 definierten Proteins, zumindest eines antigenen in Anspruch 2 oder Anspruch 3 definierten Fragments oder einer in Anspruch 4 oder Anspruch 5 definierten Antigenzusammensetzung bei der Herstellung einer immunogenen Zusammensetzung, vorzugsweise eines Impfstoffes.
EP96902390A 1995-02-15 1996-02-15 Helicobacter pylori antigen Expired - Lifetime EP0809653B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9502899 1995-02-15
GBGB9502899.9A GB9502899D0 (en) 1995-02-15 1995-02-15 Novel antigen
PCT/GB1996/000351 WO1996025430A1 (en) 1995-02-15 1996-02-15 Helicobacter pylori antigen

Publications (2)

Publication Number Publication Date
EP0809653A1 EP0809653A1 (de) 1997-12-03
EP0809653B1 true EP0809653B1 (de) 2001-09-26

Family

ID=10769595

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96902390A Expired - Lifetime EP0809653B1 (de) 1995-02-15 1996-02-15 Helicobacter pylori antigen

Country Status (18)

Country Link
EP (1) EP0809653B1 (de)
JP (1) JPH11503999A (de)
KR (1) KR19980701698A (de)
CN (1) CN1175955A (de)
AT (1) ATE206138T1 (de)
AU (1) AU714222B2 (de)
CA (1) CA2212952A1 (de)
DE (1) DE69615537T2 (de)
DK (1) DK0809653T3 (de)
ES (1) ES2164231T3 (de)
FI (1) FI973335A (de)
GB (1) GB9502899D0 (de)
IL (1) IL117151A (de)
NO (1) NO973753D0 (de)
NZ (1) NZ301334A (de)
PT (1) PT809653E (de)
WO (1) WO1996025430A1 (de)
ZA (1) ZA9601216D (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599509B2 (en) * 1997-09-02 2003-07-29 Massachusetts Institute Of Technology Compositions and methods comprising helicobacter antigens for treatment and prevention of inflammatory bowel disease
CN1105185C (zh) * 1998-11-30 2003-04-09 上海晶莹生物技术有限公司 基因表达幽门螺杆菌细胞毒素相关基因a蛋白抗原制备工艺
AUPQ854100A0 (en) * 2000-07-03 2000-07-27 Helirad Pty Ltd Methods for monitoring treatment of helicobacter infection
SE0101030D0 (sv) * 2001-03-23 2001-03-23 Nordic Bio Ab Immunogenic cell surface proteins of helicobacter pylori

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459041A (en) * 1988-02-18 1995-10-17 Enteric Research Laboratories, Inc. Campylobacter pylori antigens and uses thereof for detection of Campylobacter pylori infection
DE4139840B4 (de) * 1990-12-04 2005-06-02 Quidel Corp., San Diego Antigen-Zubereitung zum Nachweis von H. pylori
ATE167573T1 (de) * 1992-04-29 1998-07-15 Auspharm Int Ltd In vitro-test für helicobacter pylori

Also Published As

Publication number Publication date
DK0809653T3 (da) 2001-11-19
IL117151A0 (en) 1996-06-18
ZA9601216D (en) 1997-09-15
GB9502899D0 (en) 1995-04-05
DE69615537T2 (de) 2002-04-18
NO973753L (no) 1997-08-14
ES2164231T3 (es) 2002-02-16
CA2212952A1 (en) 1996-08-22
JPH11503999A (ja) 1999-04-06
PT809653E (pt) 2002-03-28
NO973753D0 (no) 1997-08-14
DE69615537D1 (en) 2001-10-31
ATE206138T1 (de) 2001-10-15
IL117151A (en) 2001-06-14
MX9706267A (es) 1997-11-29
FI973335A0 (fi) 1997-08-14
CN1175955A (zh) 1998-03-11
AU4672896A (en) 1996-09-04
FI973335A (fi) 1997-08-14
WO1996025430A1 (en) 1996-08-22
NZ301334A (en) 1999-08-30
AU714222B2 (en) 1999-12-23
EP0809653A1 (de) 1997-12-03
KR19980701698A (ko) 1998-06-25

Similar Documents

Publication Publication Date Title
US6680374B2 (en) Invaplex from gram negative bacteria, method of purification and methods of use
US7022328B1 (en) Therapeutic and diagnostic compositions
US7858345B2 (en) Immunogenic Mycoplasma hyopneumoniae polypeptides
HUE026171T2 (en) A method for treating, preventing and detecting Helicobacter infection
US20150293118A1 (en) Cross-reactive determinants and methods for their identification
EP0809653B1 (de) Helicobacter pylori antigen
CA2233570C (en) Detection, prevention and treatment of papillomatous digital dermatitis
AU2003213233B2 (en) Method of making CS6 antigen vaccine for treating, preventing, or inhibiting enterotoxigenic escherichia coli infections
JP2003521881A (ja) ローソニア由来の遺伝子及び関連ＯｍｐＨポリペプチド、ぺプチド及びタンパク質並びにそれらの使用
WO1998032768A1 (en) H. pylori antigens
MXPA97006267A (en) Antigen of helicobacter pyl
US20020071850A1 (en) Helicobacter pylori antigen
US20050232943A1 (en) Antigenic composition of a Pseudomonas aeruginosa protein
EP0456686B1 (de) Exkretorische/sekretorische antigene des bandwurms (cysticercus cellulosae) zur verwendung in der immundiagnostik und der impfstoffbereitung
US20030082170A1 (en) Protein from brucella species
JP3335622B2 (ja) 細菌からトランスフェリン及びラクトフェリン受容体タンパク質を分離及び精製する方法並びにこれらを含有するワクチンを調製する方法
CA2164701A1 (en) Pasteurella haemolytica subunit vaccine containing capsular polysaccharide and muramyl dipeptide
RU97115365A (ru) Антиген helicobacter pylori
WO2000046242A2 (en) 19 KILODALTON PROTEIN OF $i(HELICOBACTER PYLORI)
JPH0643166A (ja) 歯周疾患診断用抗体及び該抗体を利用した歯周疾患診断法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970909

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CORTECS (UK) LIMITED

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CORTECS (UK) LIMITED

17Q First examination report despatched

Effective date: 19990413

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07K 14/205 A, 7C 07K 7/06 B, 7G 01N 33/569 B, 7A 61K 39/106 B

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PROVALIS UK LIMITED

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

ITF It: translation for a ep patent filed

Owner name: BARZANO' E ZANARDO ROMA S.P.A.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

REF Corresponds to:

Ref document number: 206138

Country of ref document: AT

Date of ref document: 20011015

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: KIRKER & CIE SA

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69615537

Country of ref document: DE

Date of ref document: 20011031

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2164231

Country of ref document: ES

Kind code of ref document: T3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20020220

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20020225

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20020226

Year of fee payment: 7

Ref country code: DK

Payment date: 20020226

Year of fee payment: 7

Ref country code: AT

Payment date: 20020226

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20020227

Year of fee payment: 7

Ref country code: DE

Payment date: 20020227

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20020228

Year of fee payment: 7

Ref country code: LU

Payment date: 20020228

Year of fee payment: 7

Ref country code: IE

Payment date: 20020228

Year of fee payment: 7

Ref country code: GR

Payment date: 20020228

Year of fee payment: 7

Ref country code: CH

Payment date: 20020228

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20020315

Year of fee payment: 7

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20011218

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20020418

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20020517

Year of fee payment: 7

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20010402453

Country of ref document: GR

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030215

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030215

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030217

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030228

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030228

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030228

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030228

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030902

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030904

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

GBPC Gb: european patent ceased through non-payment of renewal fee
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031031

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20030901

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20030217

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1001975

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050215